Predictors of short-term mortality after rheumatic heart valve surgery: A single-center retrospective study

Khalid S. Ibrahim, MD, PhD a, *, Khalid A. Kheirallah, PhD b, Fadia A. Mayyas, PhD c, Nizar R. Alwaqfi, MD a, Murtada H. Alawami, MD d, Qusai M. Aljarrah, MD e

a Division of Cardiac Surgery, Department of General Surgery and Urology, College of Medicine, Jordan University of Science and Technology and Princess Muna Center for Heart Diseases and Surgery, King Abdullah University Hospital, Jordan
b Department of Public Health and Community Health, College of Medicine, Jordan University of Science and Technology, Jordan
c Department of Clinical Pharmacy, College of Pharmacy, Jordan University of Science and Technology, Jordan
d Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
e Department of Surgery, Faculty of Medicine, Jordan University of Science and Technology, Jordan

ARTICLE INFO

Keywords: Predictors Valve surgery Emergency surgery Mortality

ABSTRACT

Background: Valve replacement surgeries hold risks of morbidity and mortality. Materials and methods: The study cohort included 346 patients who underwent different types of valve surgery, excluding redo and Bentall operations. All operations were performed through a median sternotomy using cardiopulmonary bypass.

Results: Mean patient age was 51.6 ± 16.1 years, and 51% were male. Approximately 21% had diabetes, and 44.6% were hypertensive. Aortic valve replacement (AVR) was performed in 125 patients (37%), mitral valve replacement (MVR) in 95 (28%), combined AVR and MVR in 42 (13%), AVR plus coronary artery bypass grafting (CABG) in 19 (6%), and MVR plus CABG in 32 (10%). Operative mortality was 5.8% (n = 20). In the bivariate-level analysis, older age, operation type, hypertension, emergency surgery, use of a biological valve in the aortic or mitral position, pump time greater than 120 min, and aortic clamp time greater than 60 min were significant predictors of 30-day mortality. Use of medications stratified by duration (less than or more than a month) was also shown to be a predictor of mortality. Use of angiotensin-converting enzyme inhibitors, digoxin, beta-blockers, statins, and loop diuretics was associated with mortality. Older age, emergency/salvage surgery, use of beta-blockers for less than 1 month preoperatively, and use of a biological valve in the aortic position were significant and independent predictors of 30-day mortality.

Conclusion: Age, emergency valve surgery, use of a biological valve, use of beta-blockers for less than 1 month before surgery, type of surgery, EF < 35%, pump time, and cross clamp time were all found to be independent predictors of mortality in patients undergoing valve surgery. Further prospective multicenter studies may be needed to provide a comprehensive assessment of mortality in patients undergoing valve surgery in Jordan.

1. Introduction

Valvular heart disease, both stenosis and regurgitation, can cause a wide range of symptoms, including shortness of breath, chest pain, fatigue, syncopal attacks, and even sudden death. Surgical valve replacement is still the gold-standard treatment for symptomatic valve disease. In Jordan, similar to most developing countries, rheumatic valve disease is still the leading pathology, although the incidence is declining [1].

Several studies have evaluated predictors of mortality after valve replacement surgery [2–4]. In patients undergoing aortic or mitral valve surgery, older age, high creatinine, coronary artery disease and congestive heart failure (HF) were significant independent predictors of in-hospital mortality [3]. We have previously investigated predictors of mortality and morbidity following coronary artery bypass surgery (CABG) in the north of Jordan; these included older age, female sex, HF, prolonged inotropic support, increased left atrial size, and mitral regurgitation [5–7]. Valve surgery is associated with significant mortality; however, predictors have not yet been investigated in the Jordanian population.

* Corresponding author. Faculty of Medicine, Jordan University of Science and Technology, King Abdullah University Hospital, Jordan.
E-mail address: Ksibrahim@just.edu.jo (K.S. Ibrahim).

https://doi.org/10.1016/j.amsu.2021.01.077
Received 29 December 2020; Received in revised form 21 January 2021; Accepted 21 January 2021
Available online 26 January 2021
2049-0801/© 2021 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license
In this study, we investigated preoperative, intraoperative, and postoperative predictors of mortality after valve replacement surgery in Jordanian patients.

2. Patients and methods

2.1. Patients

From 2002 to 2017, 346 patients underwent isolated aortic valve replacement (AVR), isolated mitral valve replacement (MVR), AVR plus CABG, MVR plus CABG, or combined AVR and MVR with or without CABG were included in this cohort retrospective study. The study was conducted at King Abdullah University Hospital (KAUH), located in the north of Jordan. Patients who had previous cardiac surgery and those with aortic dissection requiring aortic root replacement as well as valve repair were excluded, leaving a study cohort of 346 patients for analysis.

Clinical, echocardiographic, and surgical data from the electronic medical records of eligible patients were abstracted and reviewed. Prior use of medications was documented and stratified by duration of less than or more than one month. Short-term mortality was defined as all-cause mortality within 30 days after surgery. Preoperative coronary angiography was performed for patients with an indication and for those older than age 35. The study was approved by the Institute Research Board at KAUH and Jordan University of Science and Technology. The study was registered at the “Research Registry” with unique identification number UIN of 6457. The work has been reported in line with the STROCSS criteria [8].

2.2. Operative procedure

All patients had a median sternotomy, cardiopulmonary bypass, and ascending aortic cannulation. A two-stage venous cannula was used in patients undergoing AVR and bicaval cannulation in those undergoing MVR. In patients undergoing valve replacement plus CABG, distal anastomoses to the right coronary artery and circumflex artery were done using 7/0 continuous polypropylene sutures. This was followed by valve replacement and left internal thoracic artery to left anterior descending anastomoses. AVR was performed through a transverse incision in the proximal ascending aorta about 1.5 cm distal to the origin of the right coronary artery, while MVR was performed through an interatrial incision. Pledged polyester (2/0) interrupted sutures were used in both the aortic and mitral positions after excision of the valve cusps/leaflet and proper decalcification. Age 65 years was used as the cutoff for choosing a mechanical or biological valve. All surgeries were operated by consultant cardiac surgeons certified by the Jordanian Medical Council, in addition to fellowship training in USA or North Europe and licensed to work as cardiac surgeons in Jordan by the Ministry of Health.

2.3. Statistical analysis

Data were analyzed using SPSS version 22. Categorical variables are summarized as frequencies and percentages and continuous variables as mean ± standard deviation. Distribution of independent variables for 30-day mortality is presented using X² or independent sample t-test, as appropriate. P-values for the bivariate analyses are reported. Independent variables that were significantly associated with mortality (P < 0.05) were entered in a backward conditional logistic regression model (entry at P = 0.50, removal at P = 0.1). Adjusted odds ratios (AOR) and P-values were reported. Alpha level was set at 0.05 for all analyses.

At the bivariate level, variables that were significantly associated with 30-day mortality were included in the logistic regression model. These included operation type, hypertension, emergency surgery, preoperative and intraoperative aortic balloon-pumping, type of aortic or mitral valve used, pump time, aortic clamp time, re-exploration, and prior use of medications, including aspirin, angiotensin-converting enzyme (ACE) inhibitors, digoxin, beta-blockers, statins, and loop diuretics.

3. Theory/ Calculation

There is a rising need to revisit rheumatic heart surgery in developed countries because of the increasing number of refugees immigrations where the disease was still endemic in their native home countries.

Diagnosing these patients early will improve the outcomes from valve replacement surgery. Our study may help in selecting patients who are at increased risk of mortality to provide preventable measures when possible to reduce complications and death.

4. Results

4.1. Patient characteristics

In this study, mean age was 51.6 ± 16.1 years, and 51% (n = 178) were male. About 21% of patients had diabetes, 44.6% had hypertension (Table 1), 31.8% had coronary artery disease, and 22.5% had HF. AVR was performed in 125 patients (37%), MVR in 95 (28%), combined AVR and MVR in 42 (13%), AVR plus CABG in 19 (6%), and MVR plus CABG in 32 (10%). Operative mortality was 5.8% (n = 20). Cause of death was multi-system organ failure in 10, sepsis in 6, stroke in 1, and undocumented in 3. Most of patients were on standard medical therapy for treatment of comorbidities: aspirin (33.3%), clopidogrel bisulfate (16.2%), statins (25.2%), beta-blockers (35.4), ACE inhibitors (27.8%), and loop diuretics (48.5%).

4.2. Predictors of mortality

At the bivariate level, older age (P < 0.0001), operation type (P = 0.024), hypertension (P = 0.005), emergency/salvage surgery (P = 0.041), use of a biological valve in the aortic (P = 0.001) or mitral (P = 0.029) position, pump time greater than 120 min, and aortic clamp time greater than 60 min were significant predictors of 30-day mortality. Use of medications—ACE inhibitors (P = 0.027), digoxin (P = 0.008), beta-blockers (P < 0.001), statins (P = 0.036), and loop diuretics (P = 0.003)—was also associated with mortality.

We also used logistic regression to identify independent predictors of mortality (Table 2), adjusting for other variables or potential confounders. Older patients (P = 0.028, AOR = 10.6), emergency/salvage surgery (P = 0.034, AOR = 7.12), use of beta-blockers for less than a month before surgery (P = 0.006, AOR = 8.59), and a biological valve in aortic position (P = 0.007, AOR = 7.09) were all significant and independent predictors of 30-day mortality (Table 1).

5. Discussion

Valve replacement surgery is the second most commonly performed open heart surgery in Jordan after CABG. However, independent predictors of mortality after valve operations have not been studied as widely as predictors after CABG. This paucity of data might be due to fewer valve operations being performed than CABG procedures as valve operations require more time and/or more centers to accumulate enough cases to draw conclusions. In addition, a wide range of valve procedures are performed, and the risk of mortality may vary with the type of procedure [9]. We have previously evaluated predictors of mortality and morbidity for patients undergoing CABG [5–7]. Predictors of mortality included age ≥65 years, female sex, HF, left ventricular ejection fraction (LVEF) ≤35%, prolonged inotropic support, mechanical ventilation >2 h, postoperative pneumonia, and postoperative stroke, as well as enlarged left atrial size and mitral regurgitation [5–7]. Previous studies have identified predictors of mortality in different patient populations undergoing valve surgery. In those undergoing mitral
Table 1
Represents demographic data, Pre- Intra- and Postoperative predictors of mortality after rheumatic valvular heart surgery by univariate analysis.

| Variables                                      | Not dead | Dead | OR   | P-value |
|------------------------------------------------|----------|------|------|---------|
| Overall                                        | 346 (16.1) | 50.7 (1601) | 65.6 (8.8) | 1.09 | 0.000 |
| Age in years (mean (SD))                       | 51.56 | 50.7 (1601) | 65.6 | 0.88 |
| Gender                                         |          |      |      |         |
| Female                                         | 168      | 159  | 94.6%| 5.4%    | 0.462 |
| Male                                           | 178      | 167  | 93.8%| 6.2%    | 1.16  |
| Total                                          | 346      | 326  | 94.20%| 5.80%  | -     | -     |
| Operation type                                 |          |      |      |         |
| AVR                                            | 125      | 120  | 96.0%| 5.0%    | 0.024 |
| MVR                                            | 95       | 91   | 95.8%| 4.2%    | 1.05  |
| AVR + MVR                                       | 42       | 41   | 100.0%| 0.0% | 1.12  |
| AVR + CABG                                      | 19       | 15   | 78.9%| 21.1%   | 6.40  |
| MVR + CABG                                      | 32       | 28   | 87.5%| 12.5%   | 3.43  |
| Other                                           | 33       | 21   | 95.5%| 4.5%    | 1.14  |
| Total                                          | 335      | 317  | 94.6%| 5.4%    | -     | -     |
| Stable Angina                                  |          |      |      |         |
| No                                             | 253      | 243  | 96.0%| 4.0%    | 0.249 |
| Yes                                            | 76       | 71   | 93.4%| 6.6%    | 1.71  |
| Total                                          | 329      | 314  | 94.6%| 5.4%    | 0.62  |
| Histort of CAD                                 |          |      |      |         |
| No                                             | 225      | 213  | 94.7%| 5.3%    | 0.246 |
| Yes                                            | 104      | 101  | 97.1%| 2.9%    | 0.53  |
| Total                                          | 329      | 314  | 94.6%| 5.4%    | 0.53  |
| Recent MI                                      |          |      |      |         |
| No                                             | 325      | 311  | 95.7%| 4.3%    | 0.311 |
| Yes                                            | 8        | 7    | 87.5%| 12.5%   | 3.17  |
| Total                                          | 333      | 318  | 95.5%| 4.5%    | 3.17  |
| Ever Smoking                                   |          |      |      |         |
| No                                             | 234      | 222  | 94.9%| 5.1%    | 0.339 |
| Yes                                            | 93       | 90   | 96.8%| 3.2%    | 0.62  |
| Total                                          | 327      | 312  | 95.4%| 4.6%    | 0.62  |
| COPD                                           |          |      |      |         |
| No                                             | 319      | 304  | 95.3%| 4.7%    | 0.494 |
| Yes                                            | 15       | 15   | 100.0%| 0% | 0.95  |
| Total                                          | 334      | 319  | 95.5%| 4.5%    | 0.95  |
| Hypertension                                   |          |      |      |         |
| No                                             | 185      | 182  | 98.4%| 1.6%    | 0.005 |
| Yes                                            | 149      | 137  | 91.9%| 8.1%    | 5.31  |
| Total                                          | 334      | 319  | 95.5%| 4.5%    | 5.31  |
| Diabetes                                       |          |      |      |         |
| No                                             | 259      | 248  | 95.8%| 4.2%    | 0.381 |
| Yes                                            | 68       | 64   | 94.1%| 5.9%    | 1.41  |
| Total                                          | 327      | 312  | 95.4%| 4.6%    | 1.41  |
| PVD                                            |          |      |      |         |
| No                                             | 314      | 301  | 95.9%| 4.1%    | 0.114 |
| Yes                                            | 13       | 11   | 84.6%| 15.4%   | 4.21  |
| Total                                          | 327      | 312  | 95.4%| 4.6%    | 4.21  |
| AF                                             |          |      |      |         |
| No                                             | 273      | 260  | 95.2%| 4.8%    | 0.515 |
| Yes                                            | 56       | 54   | 96.4%| 3.6%    | 0.74  |
| Total                                          | 329      | 314  | 95.4%| 4.6%    | 0.74  |
| Pre OP renal impairment                        |          |      |      |         |
| No                                             | 306      | 292  | 95.4%| 4.6%    | 0.418 |
| Yes                                            | 11       | 10   | 90.9%| 9.1%    | 2.09  |
| Total                                          | 317      | 302  | 95.3%| 4.7%    | 2.09  |
| MR                                             |          |      |      |         |
| No                                             | 141      | 133  | 94.3%| 5.7%    | 0.332 |
| Grade 1                                        | 60       | 56   | 93.3%| 6.7%    | 1.19  |
| Grade 2                                        | 55       | 55   | 100.0%| 0% | 0.00  |
| grade 3                                        | 40       | 39   | 97.5%| 2.5%    | 0.43  |
| Grade 4                                        | 25       | 23   | 92.0%| 8.0%    | 1.45  |
| Total                                          | 321      | 306  | 95.3%| 4.7%    | 1.45  |
| TR                                             |          |      |      |         |
| No                                             | 219      | 208  | 95.0%| 5.0%    | 0.153 |
| Grade 1                                        | 43       | 40   | 93.0%| 7.0%    | 1.42  |
| Grade 2                                        | 36       | 36   | 100.0%| 0% | 0.00  |
| grade 3                                        | 15       | 15   | 100.0%| 0% | 0.00  |
| Grade 4                                        | 4        | 3    | 75.0%| 25.0%   | 6.30  |
| Total                                          | 317      | 302  | 95.3%| 4.7%    | 6.30  |
| AR                                             |          |      |      |         |
| no                                             | 190      | 181  | 95.3%| 4.7%    | 0.126 |
| Grade 1                                        | 55       | 51   | 92.7%| 7.3%    | 1.58  |
| Grade 2                                        | 42       | 40   | 95.2%| 4.8%    | 1.01  |
| grade 3                                        | 25       | 25   | 100.0%| 0% | 0.00  |
| Grade 4                                        | 34       | 29   | 85.3%| 14.7%   | 3.47  |
| Total                                          | 346      | 326  | 94.2%| 5.8%    | 3.47  |
| ER                                             |          |      |      |         |
| elective                                       | 309      | 294  | 95.1%| 4.9%    | 0.041 |
| urgent                                         | 16       | 13   | 81.3%| 18.8%   | 4.52  |
| Total                                          | 325      | 307  | 95.4%| 4.6%    | 4.52  |
| ASA                                            |          |      |      |         |
| No                                             | 212      | 206  | 97.2%| 2.8%    | -     | -     |

(continued on next page)
| Variables                                      | Not dead | Dead | OR  | P-value |
|-----------------------------------------------|----------|------|-----|---------|
|                                               | n        | %    | n   | %       |
|                                               |          |      |     |         |
|                                               | Total    |      |     |         |
|                                               |          |      |     |         |
| Yes                                           | 106      | 98   | 7   | 7.5%    | Ref    |
| Total                                         | 318      | 304  | 14  | 4.4%    | 2.80   |
| Plavix                                        |          |      |     |         |
| No                                            | 273      | 263  | 96.3% | 10 | 3.7% | Ref 0.278 |
| Discontinued 7 days or less                   | 53       | 49   | 92.5% | 4  | 7.5% | 0.215 |
| Total                                         | 326      | 312  | 95.7% | 14 | 4.3% |
| ACE Inhibitors                                |          |      |     |         |
| No                                            | 238      | 227  | 95.4% | 11 | 4.6% | Ref 0.027 |
| less than a month                             | 19       | 16   | 84.2% | 3  | 15.8% | 3.87 |
| More than month                               | 73       | 72   | 98.6% | 1  | 1.4% | 0.29 |
| Total                                         | 330      | 315  | 95.5% | 15 | 4.5% |
| Digoxin                                       |          |      |     |         |
| No                                            | 211      | 201  | 95.3% | 10 | 4.7% | Ref 0.008 |
| less than a month                             | 15       | 12   | 80.0% | 3  | 20.0% | 5.03 |
| More than month                               | 100      | 98   | 98.0% | 2  | 2.0% | 0.41 |
| Total                                         | 326      | 311  | 95.4% | 15 | 4.6% |
| Aldosterone antagonist                        |          |      |     |         |
| No                                            | 269      | 258  | 95.9% | 11 | 4.1% | Ref 0.0218 |
| less than a month                             | 5        | 4    | 80.0% | 1  | 20.0% | 5.86 |
| More than month                               | 51       | 48   | 94.1% | 3  | 5.9% | 1.47 |
| Total                                         | 325      | 310  | 95.4% | 15 | 4.6% |
| B Blockers                                    |          |      |     |         |
| No                                            | 212      | 207  | 97.6% | 5  | 2.4% | Ref 0.000 |
| less than a month                             | 32       | 26   | 81.8% | 6  | 18.2% | 9.55 |
| More than month                               | 84       | 81   | 96.4% | 3  | 3.6% | 1.53 |
| Total                                         | 328      | 314  | 95.7% | 14 | 4.3% |
| Statins                                       |          |      |     |         |
| No                                            | 246      | 237  | 96.3% | 9  | 3.7% | Ref 0.036 |
| less than a month                             | 28       | 24   | 85.7% | 4  | 14.3% | 4.39 |
| more than month                               | 55       | 53   | 96.4% | 2  | 3.6% | 0.99 |
| Total                                         | 329      | 314  | 95.4% | 15 | 4.6% |
| Loop_Diuretics                                |          |      |     |         |
| No                                            | 151      | 143  | 94.7% | 8  | 5.3% | Ref 0.003 |
| less than a month                             | 26       | 22   | 84.6% | 4  | 15.4% | 3.25 |
| more than month                               | 152      | 150  | 97.8% | 2  | 2.2% | 0.24 |
| Total                                         | 329      | 315  | 95.7% | 14 | 4.3% |
| Type valve used Aortic                        |          |      |     |         |
| Mechanical                                    | 129      | 228  | 97.0% | 7  | 3.0% | Ref 0.001 |
| Biological                                    | 62       | 98   | 88.3% | 13 | 11.7% | 4.30 |
| Total                                         | 191      | 326  | 94.2% | 20 | 5.8% |
| Type valve Mitral                             |          |      |     |         |
| Mechanical                                    | 120      | 214  | 96.4% | 8  | 3.6% | Ref 0.029 |
| Biological                                    | 67       | 112  | 90.3% | 12 | 9.7% | 2.90 |
| Total                                         | 187      | 326  | 94.2% | 20 | 5.8% |
| Pump time                                     |          |      |     |         |
| <120min                                       | 224      | 216  | 96.4% | 8  | 3.6% | Ref 0.030 |
| >120min                                       | 56       | 53   | 89.9% | 6  | 10.2% | 3.05 |
| Total                                         | 346      | 269  | 95.1% | 14 | 4.9% |
| Aorta_Clamp                                   |          |      |     |         |
| No                                            | 247      | 237  | 96.0% | 10 | 4.0% | Ref 0.028 |
| Yes                                           | 99       | 89   | 89.9% | 10 | 10.1% | 2.67 |
| Total                                         | 346      | 326  | 94.2% | 20 | 5.8% |
| Intra Op Transf.                              |          |      |     |         |
| No                                            | 258      | 246  | 95.3% | 12 | 4.7% | Ref 0.0687 |
| Yes                                           | 58       | 56   | 96.6% | 2  | 3.4% | 0.73 |
| Total                                         | 316      | 302  | 95.6% | 14 | 4.4% |
| Reexploration                                 |          |      |     |         |
| No                                            | 312      | 299  | 95.8% | 13 | 4.2% | Ref 0.070 |
| Yes                                           | 10       | 8    | 80.0% | 2  | 20.0% | 5.75 |
| Total                                         | 322      | 307  | 95.3% | 15 | 4.7% |
| Prolonged support                             |          |      |     |         |
| No                                            | 266      | 256  | 96.2% | 10 | 3.8% | Ref 0.180 |
| Yes                                           | 52       | 48   | 92.3% | 4  | 7.7% | 2.13 |
| Total                                         | 318      | 304  | 95.6% | 14 | 4.4% |
| Post Op Renal Failure                         |          |      |     |         |
| No                                            | 311      | 298  | 95.8% | 13 | 4.2% | Ref 0.102 |
| Yes                                           | 12       | 10   | 83.3% | 2  | 16.7% | 4.58 |
| Total                                         | 323      | 308  | 95.4% | 15 | 4.6% |
| Pneumonia Sepsis                              |          |      |     |         |
| No                                            | 316      | 303  | 95.9% | 13 | 4.1% | Ref 0.438 |
| Yes                                           | 13       | 12   | 92.3% | 1  | 7.7% | 1.94 |
| Total                                         | 329      | 315  | 95.7% | 14 | 4.3% |
| Post Op Stroke TIA                            |          |      |     |         |
| No                                            | 324      | 310  | 95.7% | 14 | 4.3% | Ref 0.171 |
| Yes                                           | 4        | 3    | 75.0% | 1  | 25.0% | 7.38 |
| Total                                         | 328      | 313  | 95.4% | 15 | 4.6% |
| Intra OP insertion of temporary pacemaker     |          |      |     |         |
| No                                            | 230      | 219  | 95.2% | 11 | 4.8% | Ref 0.764 |
| Yes                                           | 91       | 88   | 96.7% | 3  | 3.3% | 0.68 |
| Total                                         | 321      | 307  | 95.6% | 14 | 4.4% |

(continued on next page)
mitral incompetence following acute myocardial infarction or acute pathologies that mandate emergency valve surgery, including acute referral to surgery before severe deterioration of the left ventricular function is a key step to better outcomes. Proper follow up for these patients and early understanding potential causes of mortality in our relatively young cohort of patients who receive mechanical valves. However, our model identified both age and biological valves as significant, yet independent, predictors of mortality after adjusting for other variables. In a sub-analysis in which we excluded age from the regression model, the effect of valve type was almost identical to that reported one with age in the model, suggesting that 30-day mortality is affected by age independent of valve type and vice-versa.

Beta-blockers are key medications for treating HF, myocardial infarction, and atrial fibrillation, and are useful adjuncts for hypertension management. Beta-blockers can antagonize the effects of an overactive sympathetic nervous system, which is responsible for development and progression of HF. These medications reduce myocardial oxygen demand and improve LV EF in patients with HF [13] and control heart rate in patients with mitral stenosis [14].

Due to their negative inotropic and chronotropic effects, beta-blockers may initially worsen edema, hypotension, bradycardia, and LV EF before improvement is observed, but subsequent improvement often occurs after 6–12 months of therapy [15]. The incidence and severity of beta-blockers’ adverse effects are usually dose dependent [16]. Thus, patients should be clinically monitored and their dose titrated carefully to avoid adverse outcomes. Given the different effects of beta-blockers, increasing the dosage may cause unintended side effects and significant morbidity, particularly in patients with hypotension and bradycardia, without additional benefits [16].

In our study, most of patients were on high doses of beta blockers. Interestingly, use of beta-blockers for less than 1 month before surgery increased the risk of mortality relative to that of non-users, suggesting that short-term use might worsen symptoms and increase mortality risk. To test this hypothesis, we evaluated the correlation between use of beta-blockers for less than 1 month and LV EF as well as presence of orthopnea and found a positive correlation. Current guidelines recommend beta-blocker therapy for patients with mild to moderate compensated HF, with stable New York Heart Association class II/III symptoms and on standard therapy for HF (diuretics and an ACE inhibitor) [17]. Intriguingly, beta-blockers were found to increase risk of sudden cardiac death and need for surgery in patients with chronic, severe, non-ischemic MR [18].

Interestingly, the type of surgery performed in our patients predicts mortality. The more complex the surgery, the higher the mortality. Whereas the mortality rate was around 2% among patients who underwent isolated AVR, it jumped to 7% in patients with combined AVR, MVR and CABG. These results are replicated in other studies [8]. Prolonged cardiopulmonary bypass time and X-clamp time, which were also found to be independent predictors of mortality, might explain this. In a separate analysis, we removed prolonged bypass time and X-clamp time from the model to avoid confounding, and type of surgery remained a predictor of mortality.

Taylor et al. found postoperative atrial fibrillation (POAF) to be a predictor of mortality after valve replacement surgery [4], whereas Al-Waqfi et al. found no relation [5]. Similarly, we did not find a correlation between POAF and mortality. This might be due to the low prevalence of POAF (12%) in our study. Our study results help in risk stratification of patients with increased mortality rate and help define how patients’ characteristics, underlying morbidities and type of surgery would affect the clinical outcome of

| Variables | Total | Not dead | n | % | Dead | n | OR | P-value |
|-----------|-------|----------|---|---|------|---|----|--------|
| Post OP AF |       |          |   |   |       |   |    |        |
| No        | 278   | 265      | 95.3% | 13 | 4.7%  |    |     | 0.480  |
| Yes       | 38    | 37       | 97.4% | 1  | 2.6%  |    |     | 0.55   |
| Total     | 316   | 302      | 95.6% | 14 | 4.4%  |    |     |        |

Table 2 Multivariate analysis of risk factors associated with mortality after rheumatic valvular heart surgery.

Data are presented as mean (SD) for continuous variables or percentages for categorical variables. AOR: adjusted odd ratio, AVR: aortic valve repair, MVR: mitral valve repair, CABG: coronary artery bypass surgery, CAD: coronary artery disease, MI: myocardial infarction, COPD: chronic obstructive pulmonary disease, PVD: peripheral vascular disease, AF: atrial fibrillation, MR: mitral regurgitation, TR: tricuspid regurgitation, AR: aortic regurgitation, ER: emergency surgery, Pre op: pre-operative, Post op: post-operative, IABP: intra-aortic balloon pump, TIA: transient ischemic attach, POAF: post-operative atrial fibrillation.
patients undergoing valvular surgery. Meticulous timing for performing valvular surgeries i.e before deterioration of the left ventricular function as well as proper preparation of these patients in terms of adjusting their medications and controlling the modifiable risk factors are key measures toward improving the outcome and reducing mortality. More accurate risk stratification systems are required to identify patients who may benefit from different types of valvular surgeries and or in need of an early treatment.

6. Limitations

This is a retrospective study with a limited sample size and some missing data. Data were extracted from a single center, which may not represent short-term mortality in all centers in Jordan.

7. Conclusion

Age, emergency valve surgery, use of a biological valve, and use of beta-blockers for less than 1 month before surgery, Type of surgery, EF<50%, Pump time, Cross clamp time were all found to be independent predictors of mortality in patients undergoing valve surgery. Further prospective multicenter studies may be needed to provide a comprehensive assessment of mortality in patients undergoing valve surgery in Jordan. A multicenter prospective studies are needed to investigate these predictors while eliminating the limitations of retrospective studies.

Declaration of competing interest

NO CONFLICT OF INTEREST OF ANY TYPE FOR ANY OF THE AUTHORS.

Acknowledgements

Not applicable.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| AVR          | Aortic Valve Replacement |
| MVR          | Mitral Valve Replacement |
| CABG         | Coronary Artery Bypass Grafting |
| HF           | Heart Failure |
| AOR          | Adjusted Odds Ratio |
| ACE          | Angiotensin Converting Enzyme |
| LVEF         | Left Ventricular Ejection Fraction |
| POAF         | Post Operative Atrial Fibrillation |

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2021.01.077.

Ethical approval

The study was approved my the Institute Research Board at Jordan University of Science and Technology and King Abdullah University Hospital.

Sources of funding

The study did not get any funding

Authors contributions

1. Substantial contributions to conception and design, data acquisition, or data analysis and interpretation: All Authors.

2. Drafting the article or critically revising it for important intellectual content: All Authors

3. Final approval of the version to be published: All Authors

4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved: Khalid Ibrahim.

Registration of research studies

1. Name of the registry: Research Registry
2. Unique Identifying number or registration ID: 6457
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): https://www.researchregistry.com/browse-the-registry#home/

Guanantor

Khalid S. Ibrahim, MD, PhD.
Associate Professor, Faculty of Medicine, Jordan University of Science and Technology.
Consultant Cardiac Surgeon, Faculty of Medicine, King Abdullah University Hospital, +962 79 6 42 77 00.

References

[1] L.W. Chen, J. Chen, J.N. Zheng, Y.N. Ke, Q.F. Zhu, Y.M. Ni, et al., Prediction of short-term mortality after valve surgery: a single center’s perspective, Chin. Med. J. (Engl.) 131 (20) (2018) 2499–2502.
[2] M. Enriquez-Sarano, H.V. Schaff, T.A. Orszulak, A.J. Tajik, K.R. Bailey, R.L. Pye, Valve repair improves the outcome of mitral regurgitation. A multivariate analysis, Circulation 91 (4) (1995) 1022–1028.
[3] E.R. Nowicki, N.J. Birkmeyer, R.W. Weintraub, B.J. Levitt, J.H. Sanders, L. J. Dacey, et al., Multivariable prediction of in-hospital mortality associated with aortic and mitral valve surgery in Northern New England, Ann. Thorac. Surg. 77 (6) (2004) 1966–1977.
[4] N.E. Taylor, S. O’Brien, F.H. Edwards, E.D. Peterson, C.R. Bridges, Relationship between race and mortality and morbidity after valve replacement surgery, Circulation 111 (10) (2005) 1305–1312.
[5] N. Alwaqfi, Y. Khader, K. Ibrahim, Coronary artery bypass: predictors of 30-day operative mortality in Jordanians, Asian Cardiovasc. Thorac. Ann. 20 (3) (2012) 245–251.
[6] N.R. Alwaqfi, Y.S. Khader, K.S. Ibrahim, F.M. Equb, Coronary artery bypass grafting: 30-day operative morbidity analysis in 1046 patients, J. Clin. Med. Res. 4 (4) (2012) 267–273.
[7] K.S. Ibrahim, F.A. Mayyas, K. Kheirallah, N.R. Alwaqfi, D.R. Van Wagoner, Is left atrial size a predictor of mortality after coronary artery bypass surgery? A single center study, Acta Cardiol. Sin. 33 (2) (2017) 195–203.
[8] R. Agha, A. Abdall-Razak, E. Crossley, N. Dowlut, C. Iosifidis, G. Mathew, et al., STROCSS 2019 Guideline: strengthening the reporting of cohort studies in surgery, Int. J. Surg. 72 (2019) 156–165.
[9] E.L. Hannan, M.J. Racz, R.H. Jones, J.P. Gold, T.J. Ryan, J.P. Hafner, et al., Predictors of mortality for patients undergoing valve surgery in Northern New York State, Ann. Thorac. Surg. 70 (4) (2000) 1212–1218.
[10] M.F. Khan, M.S. Khan, F.I. Bawany, M.I. Dar, M. Hussain, S. Farhan, et al., Predictors of mortality in patients undergoing mitral valve replacement, Global J. Health Sci. 8 (3) (2015) 37–42.
[11] S. Mkalaluh, M. Szczezewicz, B. Dib, G. Szabo, M. Karck, A. Weymann, Outcomes and predictors of mortality after mitral valve surgery in high-risk elderly patients: the Heidelberg experience, Med. Sci. Mon. Int. Med. J. Exp. Clin. Res. 23 (2017) 6193–6200.
[12] Y.S. Tjang, Y. van Hees, R. Korfer, D.E. Grobbee, J.P. Hafner, et al., Multivariable prediction of in-hospital mortality associated with aortic and mitral valve surgery in Northern New England, Ann. Thorac. Surg. 77 (6) (2004) 1966–1977.
[13] E.A. Russell, W.F. Walsh, B. Costello, A.J.A. McLellan, A. Brown, C.M. Reid, et al., Medical management of rheumatic heart disease: a systematic review of the evidence, Cardiol. Rev. 26 (4) (2018) 187–195.
[14] M. Gheorghiade, R.J. Cody, G.S. Francis, W.J. McKenna, J.B. Young, R.D. Bonow, Current medical therapy for advanced heart failure, Heart Lung 29 (1) (2000) 16–32.
[16] S.B. Dimmitt, H.G. Stampfer, J.B. Warren, beta-adrenoceptor blockers valuable but higher doses not necessary, Br. J. Clin. Pharmacol. 78 (5) (2014) 1076–1079.

[17] W.T. Abraham, Beta-blockers: the new standard of therapy for mild heart failure, Arch. Intern. Med. 160 (9) (2000) 1237–1247.

[18] P.G. Supino, O.Y. Hai, A. Sharma, J. Lampert, C. Hochreiter, E.M. Herrold, et al., Impact of beta-blockade on cardiac events in patients with chronic severe nonischemic mitral regurgitation, Cardiology 139 (1) (2018) 1–6.